A non-oncogenic HPV 16 E6/E7 vaccine enhances treatment of HPV expressing tumors.
about
Synergistic anti-cancer effect of phenformin and oxamate.The clinical impact of HPV tumor status upon head and neck squamous cell carcinomas.CD137 enhancement of HPV positive head and neck squamous cell carcinoma tumor clearance.Stereotactic body radiotherapy for recurrent oropharyngeal cancer - influence of HPV status and smoking history.Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancerDepletion of tumor-associated macrophages enhances the anti-tumor immunity induced by a Toll-like receptor agonist-conjugated peptide.A DNA vaccine encoding mutated HPV58 mE6E7-Fc-GPI fusion antigen and GM-CSF and B7.1.Frequency and genotype of human papillomavirus among Sudanese patients with head and neck tumoursDe-escalation of radiation dose for human papillomavirus-positive oropharyngeal head and neck squamous cell carcinoma: A case report and preclinical and clinical literature review.Enhanced Cytotoxic CD8 T Cell Priming Using Dendritic Cell-Expressing Human Papillomavirus-16 E6/E7-p16INK4 Fusion Protein with Sequenced Anti-Programmed Death-1.Chimeric HBcAg virus-like particles presenting a HPV 16 E7 epitope significantly suppressed tumor progression through preventive or therapeutic immunization in a TC-1-grafted mouse model.Self-adjuvanting lipoimmunogens for therapeutic HPV vaccine development: potential clinical impact.An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression.De-oncogenic HPV E6/E7 vaccine gets enhanced antigenicity and promotes tumoricidal synergy with cisplatin.Identification and characterization of enhancer agonist human cytotoxic T-cell epitopes of the human papillomavirus type 16 (HPV16) E6/E7.β-Adrenergic receptor modulates mitochondrial metabolism and disease progression in recurrent/metastatic HPV(+) HNSCC
P2860
Q34400208-39A50441-4EB8-4427-B9F8-B14C6FCEEDDEQ35344832-B6FE1FBC-42B1-468E-ABEC-016BFD582436Q35600651-4655862F-EDEF-499E-998B-1881D09FD7A9Q35861606-5824FAC1-DD85-429A-8187-4CFE0D62AFCBQ35864700-CEF1EA1B-5FF7-4A21-AC9C-242F05A03EA1Q35886752-937DB077-EF4D-4672-9393-D70C7AC760FFQ36244253-CF42BA8A-C6E1-47FA-821A-1E6FAF635FD4Q36440782-7B829646-D08D-41D9-BCAE-4A6CC3971111Q36502676-C2D626E3-9FEF-4443-B694-9C029D00D95BQ36656025-BBA0A17D-AC4E-4A74-BC0D-60CBE3464158Q36967911-93E372FD-882F-4663-BA85-01A287F50790Q38279548-823C343A-BEE8-4DFB-8D67-5B4B5713536AQ38838178-1479114E-01B9-47D4-9413-402853F742DEQ39062363-4EF95DFA-633C-4C8F-953E-DA7BD436995CQ40252793-4F58872D-331D-4820-B6BC-B3423E3AC09EQ57295721-9D62099E-8EDA-4F3B-A71D-C22267C5A454
P2860
A non-oncogenic HPV 16 E6/E7 vaccine enhances treatment of HPV expressing tumors.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
A non-oncogenic HPV 16 E6/E7 vaccine enhances treatment of HPV expressing tumors.
@ast
A non-oncogenic HPV 16 E6/E7 vaccine enhances treatment of HPV expressing tumors.
@en
type
label
A non-oncogenic HPV 16 E6/E7 vaccine enhances treatment of HPV expressing tumors.
@ast
A non-oncogenic HPV 16 E6/E7 vaccine enhances treatment of HPV expressing tumors.
@en
prefLabel
A non-oncogenic HPV 16 E6/E7 vaccine enhances treatment of HPV expressing tumors.
@ast
A non-oncogenic HPV 16 E6/E7 vaccine enhances treatment of HPV expressing tumors.
@en
P2093
P2860
P356
P1433
P1476
A non-oncogenic HPV 16 E6/E7 vaccine enhances treatment of HPV expressing tumors.
@en
P2093
B G Wieking
D W Vermeer
E S Gabitzsch
J P Balint
S Balcaitis
W C Spanos
P2860
P2888
P304
P356
10.1038/CGT.2012.55
P577
2012-08-24T00:00:00Z